Shattuck Labs Details $72.4M Capital Raise & Extends Cash Runway into 2029

summarizeSummary

Shattuck Labs, Inc. filed its annual 10-K report, detailing a significant $72.4 million capital raise through a private placement and ATM offering, extending its cash runway into 2029, and providing updates on its clinical pipeline.

check_boxKey Events

• Extended Cash Runway

  Management projects existing capital, plus full exercise of outstanding common stock warrants, will fund operations into 2029.

• Significant Capital Raises

  The company completed a $45.7 million private placement in August 2025 and sold $21.4 million in common stock through an At-The-Market (ATM) facility in January 2026. An additional $5.3 million was raised from warrant exercises in January 2026.

• Pipeline Advancement

  The Phase 1 clinical trial for lead candidate SL-325 is expected to complete in Q2 2026, with a Phase 2 trial in Crohn's Disease planned for initiation in Q3 2026.

• Program Discontinuation

  The SL-172154 program was discontinued in October 2024, leading to a 40% workforce reduction and $1.0 million in termination benefits.

auto_awesomeAnalysis

This 10-K filing provides comprehensive financial and operational updates, detailing a significant capital raise that is crucial for the company's clinical-stage operations. The reported cash and short-term investments of $78.1 million as of December 31, 2025, combined with recent capital raises, are projected to fund operations into 2029, contingent on the full exercise of outstanding common stock warrants. This extended runway is a critical positive for a biotech with an accumulated deficit of $430.5 million. The company also provided key updates on its lead candidate, SL-325, with Phase 1 completion expected in Q2 2026 and Phase 2 initiation in Crohn's Disease in Q3 2026. Investors should monitor the actual exercise of warrants and the progress of the SL-325 clinical trials.